Testing effectiveness (Phase 2)Ended earlyNCT02454842
What this trial is testing
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
Who this might be right for
Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
Rain Oncology Inc 21